LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Operating Income
-$29.7m
CAGR 3-Years
13%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Operating Income
$36.8m
CAGR 3-Years
-4%
CAGR 5-Years
-12%
CAGR 10-Years
27%
ProQR Therapeutics NV
NASDAQ:PRQR
Operating Income
-€44.4m
CAGR 3-Years
14%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Uniqure NV
NASDAQ:QURE
Operating Income
-$179.9m
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-12%
argenx SE
XBRU:ARGX
Operating Income
-$14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Operating Income
-$371.2m
CAGR 3-Years
-42%
CAGR 5-Years
-37%
CAGR 10-Years
-30%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.55 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Operating Income?
Operating Income
-29.7m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Operating Income amounts to -29.7m USD.

What is LAVA Therapeutics NV's Operating Income growth rate?
Operating Income CAGR 5Y
-25%

Over the last year, the Operating Income growth was 32%. The average annual Operating Income growth rates for LAVA Therapeutics NV have been 13% over the past three years , -25% over the past five years .

Back to Top